ArticleFunction (Oxford, England)2026
Machine learning integrated extracellular vesicle proteome analysis for early markers of bronchopulmonary dysplasia.
Article in Function (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchopulmonary dysplasia (BPD) is a serious and often lethal complication of preterm birth that typically manifests about 1 mo after preterm delivery. The lungs of premature infants are underdeveloped and vulnerable to mechanical damage, inflammation, and oxidative stress. Collectively, these stressors impair the normal alveolarization of the premature lungs after birth. The multifactorial pathophysiology of BPD necessitates the identification of the molecular factors that mediate cell-to-cell communication that discriminates normal lung development from progression to BPD. Extracellular vesicles (EVs) mediate intercellular cross talk by transporting functional molecules, including proteins and nucleic acids, to recipient cells through biological fluids. This feasibility study determined the utility of profiling the discarded plasma-derived EV proteome to predict BPD susceptibility risk in extremely preterm infants. Discarded plasma was obtained from routine laboratory draws from infants born at less than 32 wk of gestation and weighing less than 1,500 g. Plasma EVs were captured using a magnetic bead-based immunoaffinity method. Subsequently, mass spectrometry and differential protein content analysis workflow identified a novel nine-EV-protein signature [APOD, heterogenous nuclear ribonucleoprotein M (HNRNPM), high-mobility group nucleosome-binding domain-containing protein 2 (HMGN2), intelectin-1 (ITLN1), proteinase 3 (PRTN3), RNA-binding protein4 (RBM4), RNA-binding motif protein, X chromosome (RBMX), TATA-binding protein-associated factor 2 N (TAF15, transcription elongation regulator 1 (TCERG1)] that distinguished preterm infants who developed BPD from those who did not. Application of machine learning statistical modeling using Promor tool trained on the nine-protein signature template identified a high specificity and selectivity prognostic threshold for the development of BPD. HNRNPM emerged as the most consistent biological response component predicting development of BPD in our patient cohort. Our study suggests that circulating EVs derived from discarded plasma are a suitable "liquid biopsy" to help stratify the vulnerability risk for BPD in preterm infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.